{
    "clinical_study": {
        "@rank": "127674", 
        "acronym": "ePAD", 
        "arm_group": [
            {
                "arm_group_label": "edoxaban/aspirin", 
                "arm_group_type": "Experimental", 
                "description": "Open label edoxaban will be provided. Subjects randomized to this treatment arm will receive edoxaban 60 mg once daily (QD) (two 30 mg tablets) for a total of approximately 3 months on a background of aspirin 100 mg QD."
            }, 
            {
                "arm_group_label": "clopidogrel/aspirin", 
                "arm_group_type": "Active Comparator", 
                "description": "Open label clopidogrel will be provided. Subjects randomized to this treatment arm will receive clopidogrel 75 mg QD (one 75 mg tablet) for a total of approximately 3 months on a background of aspirin 100 mg QD. A loading dose of clopidogrel 300 mg (four 75mg tablets) will be given to subjects as the first dose as early as possible after adequate hemostasis (i.e., within 4 hours of hemostasis)."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a randomized, open-label, blinded endpoint, parallel-group, active-control,\n      multi-center, proof-of-concept study in subjects with Peripheral Arterial Disease (PAD),\n      designed to assess the safety and potential efficacy of adding edoxaban to aspirin following\n      femoropopliteal endovascular intervention, with or without stent placement, relative to\n      current treatment practice with clopidogrel and aspirin."
        }, 
        "brief_title": "Edoxaban in Peripheral Arterial Disease", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Arterial Disease", 
        "condition_browse": {
            "mesh_term": [
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects older than the minimum legal adult age (country specific);\n\n          -  Rutherford stages 2-5 provided there are no ulcerations on the heel and/or exposed\n             tendon and/or bone;\n\n          -  Superficial femoral above knee-popliteal ( 3 cm proximal to the medial femoral\n             condyle) lesion and \u2265 50% stenosis or occlusion;\n\n          -  At least one run-off vessel to the foot with or without additional endovascular\n             intervention;\n\n          -  Successful intervention, defined as angiographic confirmation of \u2264 30% residual\n             stenosis and absence of flow limiting dissection;\n\n          -  Adequate hemostasis at the vascular access site within 24 hours of intervention;\n\n          -  A subject is also eligible if they have undergone additional successful endovascular\n             intervention(s) during the index intervention;\n\n          -  Able to provide signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Calculated Creatinine Clearance < 30 ml/min;\n\n          -  Femoral or popliteal aneurysm;\n\n          -  Adjunctive use of thrombolytics;\n\n          -  Any extravasation or distal embolization not successfully treated;\n\n          -  Uncontrolled hypertension as judged by the investigator (e.g., systolic blood\n             pressure > 170 mmHg or diastolic blood pressure > 100 mmHg despite\n             antihypertensives);\n\n          -  Aspirin intolerance;\n\n          -  Clopidogrel intolerance;\n\n          -  Contraindication for anticoagulants or antiplatelets and any other contraindication\n             listed in the local labeling of aspirin and/or clopidogrel;\n\n          -  Active bleeding or known high risk for bleeding or history of intracranial, or\n             spontaneous intraocular, spinal retroperitoneal or intra-articular bleeding; overt\n             gastrointestinal (GI) bleeding or active ulcer within the previous year;\n\n          -  Subjects receiving dual antiplatelet or anticoagulant therapy at the time of\n             randomization; subjects receiving pre-interventional loading dose of clopidogrel or\n             other P2Y12 receptor antagonists;\n\n          -  Treatment with cilostazol within 24 hours of randomization;\n\n          -  Subjects receiving prohibited concomitant medications [fibrinolytics, chronic use of\n             non steroidal anti-inflammatory drugs (NSAIDS) > 4 days per week, and oral or\n             parenteral non-aspirin NSAIDs and strong P-gp inhibitors];\n\n          -  Prior stroke or MI or acute coronary syndrome within 3 months;\n\n          -  Chronic liver disease [alanine transaminase (ALT) and/or aspartate transaminase (AST)\n             \u2265 2 \u00d7 upper limit of normal; total bilirubin (TBL) \u2265 1.5 \u00d7 upper limit of normal];\n             however, subjects whose elevated TBL is due to known Gilbert\u201fs syndrome may be\n             included in the study;\n\n          -  Prior history of a positive test for Hepatitis B antigen or Hepatitis C antibody;\n\n          -  Subjects who received any investigational drug or device within 30 days prior to\n             randomization, or plan to receive such investigational therapy during the study\n             period;\n\n          -  Subjects previously randomized to an edoxaban (DU-176b) study;\n\n          -  Women of childbearing potential without proper contraceptive measures (i.e. a method\n             of contraception with a failure rate < 1 % during the course of the study including\n             the observational period) and women who are pregnant or breast feeding;\n\n          -  Subjects with the following diagnoses or situations:\n\n        Active malignancy except for adequately treated non-melanoma skin cancer or other\n        non-invasive or in-situ neoplasm (e.g., cervical cancer in situ); Concurrent treatment\n        with cancer therapy (drugs, radiation, and/or surgery); Other significant active\n        concurrent medical illness or infection; Life expectancy < 12 months;\n\n          -  Subjects who are unlikely to comply with the protocol (e.g., uncooperative attitude,\n             inability to return for subsequent visits, and/or otherwise considered by the\n             Investigator to be unlikely to complete the study);\n\n          -  Subjects with any condition that, in the opinion of the Investigator, would place the\n             subject at increased risk of harm if he/she participated in the study;\n\n          -  History of heparin-induced thrombocytopenia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802775", 
            "org_study_id": "DU176b-E-U210"
        }, 
        "intervention": [
            {
                "arm_group_label": "edoxaban/aspirin", 
                "intervention_name": "edoxaban", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "clopidogrel/aspirin", 
                "description": "75mg tablet", 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug", 
                "other_name": "Plavix"
            }, 
            {
                "arm_group_label": [
                    "edoxaban/aspirin", 
                    "clopidogrel/aspirin"
                ], 
                "intervention_name": "Aspirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Clopidogrel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beverly Hills", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hollywood", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lewiston", 
                        "country": "United States", 
                        "state": "Maine"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Flint", 
                        "country": "United States", 
                        "state": "Michigan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ypsilanti", 
                        "country": "United States", 
                        "state": "Michigan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Teaneck", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Camp Hill", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Innsbruck", 
                        "country": "Austria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edgem", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ghent", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bad Krozingen", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Afula", 
                        "country": "Israel"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel Hashomer", 
                        "country": "Israel"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Austria", 
                "Belgium", 
                "Germany", 
                "Israel", 
                "Netherlands", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention", 
        "overall_contact": {
            "email": "Recruitment@Medpace.com", 
            "last_name": "Medpace Recruiting"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The proportion of subjects with major, major or clinically relevant non-major and all bleedings at 6 months.", 
                "measure": "bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "The difference in proportions of patients with re-stenosis/re-occlusion at the treated segments(s)/s between treatment groups at 6 months.", 
                "measure": "proportion of patients with re-stenosis/re-occlusion", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802775"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The proportion of subjects with major, major or clinically relevant non-major and all bleedings at 6 months will be estimated for each treatment group and summarized with 95% CI. The difference in the proportion between the two groups at each of the time points will be estimated with a 95% confidence interval (CI).", 
                "measure": "bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "number of subjects with any bleeding (major, clinically relevant non-major, and minor bleeding) occurring during treatment or within 3 days of interrupting or stopping study drug", 
                "measure": "any bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "number of clinical and laboratory safety events with description of event including adverse events (AEs), serious adverse events (SAEs), and other events of special interest (i.e., hepatic events).", 
                "measure": "safety assessments", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "number of Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI)/non-fatal stroke and death from cardiovascular causes", 
                "measure": "Major Adverse Cardiovascular Events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "number of amputations and description of event", 
                "measure": "amputations", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "number of all cause mortalities and description of event", 
                "measure": "all cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Daiichi Sankyo Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "UMC Utrecht", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Daiichi Sankyo Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}